Aspirin for primary prevention of coronary heart disease
Editorial Group: Cochrane Heart Group
Published Online: 26 JAN 2004
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
How to Cite
Jackson PPR, Aarabi M, Wallis E. Aspirin for primary prevention of coronary heart disease (Protocol). Cochrane Database of Systematic Reviews 2004, Issue 1. Art. No.: CD004586. DOI: 10.1002/14651858.CD004586.
- Publication Status: Edited (no change to conclusions)
- Published Online: 26 JAN 2004
This is the protocol for a review and there is no abstract. The objectives are as follows:
To determine the effects, both harmful and beneficial of aspirin in the primary prevention of coronary heart disease.
Does aspirin prevent fatal and non-fatal CHD in people without symptomatic vascular disease?
Does aspirin reduce all-cause and cardiovascular mortality?
Are the effects of aspirin, be they harmful or beneficial, affected by underlying risk of CHD?
Do the major adverse effects of Aspirin ever outweigh its benefit and is this balance affected by underlying CHD risk?